Meeting
2024 ASCO Annual Meeting
First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study.
Authors
Geoffrey Chong
Grampians Health, Ballarat, Australia
Geoffrey Chong , Denise Lee , Sze Ting Lee , Anneke Grobler , Richard Khor , Belinda A. Campbell , Thanuja Thachil , Kate Manos , Arina Martynchyk , Genevieve Douglas , Colm Keane , Jodie Palmer , Eliza Anne Hawkes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04962126
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 7070)
DOI
10.1200/JCO.2024.42.16_suppl.7070
Abstract #
7070
Poster Bd #
53
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led study.
First Author: Geoffrey Chong
Poster
2021 ASCO Annual Meeting
Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study.
First Author: Eliza Anne Hawkes
Poster
2022 ASCO Annual Meeting
Frontline treatment of follicular lymphoma with atezolizumab and obinutuzumab, with and without radiotherapy (The FLUORO study).
First Author: Eliza Anne Hawkes
Poster
2022 ASCO Annual Meeting
Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
First Author: Lorenzo Falchi